ArticleMolecular pharmaceutics2026
Pulsatile Release of Human Gonadotropin Releasing Hormone Using a Photoactivated Depot Containing an Unusual Light Cleaved Functionality.
Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In this work, we demonstrate that the photoactivated depot (PAD) approach can be used to produce pulsatile release of human gonadotropin releasing hormone (GnRH) using green light. Pulsatile release is critical for a range of hormones and produces distinct physiological responses in comparison with continuous release. In particular, this has been observed with the use of GnRH for the treatment of cognitive impairment in Down syndrome. We have synthesized a GnRH PAD material utilizing a green light activated nonpolar tag based on the thiocoumarin photocleavable group. This material is essentially insoluble, as required of depots in the PAD approach. Upon photolysis, it releases native soluble GnRH. A major synthetic challenge for the synthesis of this PAD was that GnRH has neither of the standard functional groups previously utilized (carboxyl or amine) to link to the light-activated, solubility controlling moiety. Using proteolysis and de novo peptide sequencing, we demonstrate that GnRH is modified via the guanidino group of arginine, making an unusual linkage. We demonstrate that this material is highly stable toward chemical hydrolysis and releases pulses of soluble GnRH in response to pulses of 500 nm light.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.